Status: Recruiting
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.
Participants needed: 12
Trial details
Phase: Phase 2Age: 16-75Biological sex: AllType: InterventionalSponsor: NeuroPro Therapeutics, Inc.Updated: May 29, 2026Locations: 1
Eligibility criteria
Subject is capable of and provides consent/assent, and the study participant's p... [+9]
Subject has metabolic or mitochondrial encephalopathies, seizures associated wit... [+17]